Original Article
Role of Intravitreal Bevacizumab (Avastin) in
Diffuse Diabetic Macular Edema
Rafeen Talpur, Muhammad
Jawed, Fariha S. Wali, Faisal Taqvi, Shehnilla Shujaat
Pak J Ophthalmol 2018, Vol. 34, No. 3
. . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See
end of article for authors
affiliations …..……………………….. Correspondence
to: Dr.
Muhammad Jawed Department
of Ophthalmology, Sindh Institute of
Ophthalmology and Visual Sciences Hyderabad, Pakistan. E-mail: jawedbiotech@yahoo.com |
Purpose: To
observe the changes in best corrected Visual Acuity (VA) and central macular
thickness after intravitreal injection of Bevacizumab (Avastin) in patients
suffering from diffuse macular edema. Study Design:
Observational study. Place
and Duration of Study: Sindh Institute of Ophthalmology and
Visual Sciences, Hyderabad, Sindh. From July 2017 to December 2017. Material and Methods: 50 eyes from 29 patients suffering
from diffuse Diabetic Macular Edema (DME) were given intravitreal bevacizumab.
Patients with VA ≤ 20/60, HBA1C ≤ 7.5 % were included. While,
patients with high diabetic profile, high blood pressure, increased blood
urea and creatinine level and past history of stroke were excluded. Slit-lamp
examination was performed to observe the number of anterior chamber cells.
Best corrected VA investigated by early treatment diabetic retinopathy study
(ETDRS) chart and complete ocular examination was performed on each patient.
Swept source Optical Coherence Tomography (OCT) was used for the measurement
of Central Macular Thickness (CMT). Results: 50 eyes of 29 patients between 35 and 75
years of age (mean 49.28 ± 8.16 years) were given Intravitreal injection of
Bevacizumab. The Base line VA & central macular thickness mean were
noted, significant increase in VA & decrease in macular thickness after 3
months of 3rd administration of injection Avastin was confirmed by
OCT. Two way ANOVA was used to analyze the data. Conclusion:
Bevacizumab plays an important role in reducing diabetic macular
edema and improving vision. Stability and increase in VA was observed and CMT
in diabetic macular edema was decreased after intravitreal injection of
bevacizumab. Key Words: Bevacizumab, Diabetic macular edema,
Vascular endothelial Growth Factor |
Diabetic retinopathy (DR) is one of the major causes of visual disorders
in actively working population in the world1. Moreover,
in developing countries DR has been demonstrated as a chief cause of blindness.
Leakage of macular capillaries results in Diabetic macular edema (DME) which is
the main reason of visual impairment in proliferative and non-proliferative DR2,3.
Vascular permeability factor, also known asVascular Endothelial
Growth Factor (VEGF), is a single protein which causes the phosphorylation of
tight proteins that stimulates the formation of blood vessels and hence
increases the permeability of retinal vessels4. Similarly,
VEGF gene is known to induce its transcription by hypoxia and has been reported
to be a major inducer of VEGF gene transcription5,6. Patients
suffering from proliferative diabetic retinopathy (PDR) have been found with
higher levels of VEGF in ocular fluids7. In
addition, when normal eyes of experimental animals were inoculated with VEGF,
they resulted with micro aneurysm formation and higher vascular permeability
which are the same pathological conditions seen in the patients of diabetic
retinopathy8,9. Retinal
neovascularization and macular edema have also been shown to be affected by VEGF10,11. Treatments
with anti VEGF drugs have been proved as a substitute for the management of diffuse
Diabetic Macular Edema (DME)12and Retinal Neovascularization (RN)13.
Bevacizumab (Avastin) is a drug used in the treatment of diabetic
eye diseases, age related macular degeneration (AMD) and other retinal
disorders. It is a full length protein which binds to all families of VEGF and
has been used systemically in tumor therapy14. Intravitreal
injection of Avastin has been reported as a useful drug in the suppression of choroidal
neovascularization, macular edema due to central retinal vein occlusion (CRVO),
vascular permeability and fibro-vascular proliferation. Furthermore, intravitreal
injection of Avastin does not seem to be harmful at high concentration in the retina
of albino rabbit18.
Compared with laser, Anti VEGF drugs have been reported more
effective. Avastin is extensively used off-label as an intravitreal management of
macular edema due to other causes10. In the following
study, we investigated the role of anti VEGF Bevacizumab (Avastin) in patients
suffering from DME wherein, VEGF is the main mediator of vascular permeability
and plays a key role in the catabolism of retinal blood barrier.
MATERIAL
AND METHODS
50 eyes of 29 patients of diffuse DME were recruited in this study.
It was accepted by Institutional Review Board (IRB) of SIOVS. The diagnosis of diffuse
DME was investigated by swept source OCT.
Inclusion criteria comprised of best-corrected VA ≤
20/60, Glycated Hemoglobin ≤ 7.5%, any
gender, patients with type 2 Diabetes Mellitus, aging between 35 to 75 years. Diffuse
DME criteria was defined as hard retinal exudates within 500µm of the macular center,
1 disc diameter or greater retinal edema, any part of which was under the limit
of 1 disc diameter of center of macular area. Exclusion criteria comprised of patients
with bleeding disorders, any infection of cornea, former treatment of Avastin,
recent history of heart attack, hypertension and former history of laser either
focal or grid.
All patients were selected through
retina clinic of Sindh Institute of ophthalmology & visual science (SIOVS),
Hyderabad, after fulfilling the inclusion criteria. Objectives and methods of
study were explained and then consent form was signed from each individual.
Slit
lamp examination was done in each patient. Swept source OCT was performed for
assessment of macular thickness before administration of Avastin. Anti VEGF
Bevacizumab (Avastin, 1.25 mg/
0.05 mL) was injected intravitreal by monthly interval for three months. It was
injected after local anesthesia, 3.5 mm in pseudophakic and 4 mm in phakic
patients away from limbus. Swept source OCT was performed on all patients 3
months after anti VEGF injection. Outcome was observed on the basis of decrease
in central macular thickness (CMT) and improvement in visual acuity. Swept
source OCT was performed to confirm the effect of anti VEGF (Avastin) in diffuse
DME. Data was analyzed using SPSS version 24.
RESULTS
A total of 50 eyes of 29
patients were selected during this study. Among whom, 32 eyes were from males
and 18 from females. Avastin was injected intravitreal in all 50 eyes of 29
patients. Patients’ ages ranged between 35 and 75 years (mean 49.28 ± 8.16
years). All patients selected in this
study were Non-Insulin Dependent Diabetic (NIDDM), had diffuse DME, which was
confirmed by swept source OCT.
The baseline VA mean
& CMT mean were noted, significant increase in VA & decrease in macular
thickness after 3 months of 3rd administration of injection Avastin
was confirmed by OCT. During this 3 months study, there were no complains of
intraocular irritation, endophthalmitis, enhanced IOP and detachment of retina.
Statistical analysis of OCT and visual acuity (VA) are described
in table1 and table 2, respectively.
Table1:
Descriptive statistics of OCT at baseline and after 3 months of intravitreal
injection of Avastin.
|
N
|
CMT (µM) Minimum
|
CMT (µM) Maximum
|
Mean
|
SD
|
Baseline
|
50
|
300
|
595
|
372.14
|
77.60
|
1
Month
|
50
|
250
|
389
|
323.19
|
73.82
|
3
Months
|
50
|
166
|
498
|
278.94
|
75.86
|
P
Value
|
|
|
|
0.03904*
|
|
SD –
Standard Deviation
Table 2: Descriptive statistics of
Visual Acuity (VA) at baseline and after 3 months of intravitreal injection of
Avastin.
|
N
|
Minimum
|
Maximum
|
Mean
|
SD
|
VA pre
|
50
|
0.3
|
1.0
|
0.692
|
0.1915
|
Et1
|
50
|
0.2
|
1.0
|
0.540
|
0.2306
|
Et3
|
50
|
0.2
|
1.0
|
0.438
|
0.2423
|
P Value
|
|
|
|
0.02804*
|
|
VA
Pre – Baseline ETDRS Visual Acuity, Et1 – ETDRS Visual Acuity at one month, Et3
– ETDRS Visual Acuity after three months
SD –
Standard Deviation
DISCUSSION
The most frequent
complication in diabetic patients is diffuse DME, which is a significant cause
of visual impairment in these patients. Due to increase in extracellular fluid,
the level of vision decrease, as a result barriers within the retinal blood
vessels due to accumulation of this extracellular fluid.
It has been reported that DME and VEGF are affected by retinal
hypoxia, which increases vascular permeability of macula, leads to DME in
patients of diabetes. Bevacizumab is known to produce quick result in recovery
of macular edema.
As demonstrated in the section
‘results’, a total of 50 eyes from 29 patients were examined during this
research. All the eyes were given Intravitreal injection of Avastin, which lead
to functional and physiological betterment. Central macular thickness (CMT)
before administration of injection Avastin ranged from 300 to 595 µm with a
mean of 372.14 µm.
Fig. 1: Comparison of Visual Acuity
(VA); VA PRE – at baseline. VA1 – VA after 1 month, VA3 – VA after 3 months.
As shown in figure 1, after one
month of administration of Avastin, significant decrease in visual acuity was
observed with a mean of 0.540 µm. On the other hand, mean CMT decreased
noteworthy up to 323.19 ± 32.58 µm ranging from 250.78 to 389.76 µm. 46
eyes showed increased in VA, while 4 eyes showed no difference in VA.
Fig. 2: Comparison of Central Macular
Thickness at baseline (Before) and after three months of injection Avastin.
After three months of the treatment with injection Avastin, there
was a noteworthy decrease in CMT, ranging from 166 to 498 µm in all 50 patients
with a mean of 278µm measured from swept source OCT (Fig. 2). 47 eyes showed
reduction in macular thickness and only 3 eyes showed minor increase in macular
thickness. Mean VA before injected injection Avastin was 0.692. During this
study, no systemic side effects were noticed and bevacizumab was well
tolerated. There was no evidence of ocular inflammation, correspondingly,
Optical tolerance was also good. As compared with the study reported by
Haritoglou et al.20 our
research proved noteworthy decease in CMT and improvement in Visual Acuity. Recently,
Chen et al described the mechanism and
Fig. 3(A): Central macular thickness
before injection Avastin 474µm, measured by swept source 3D Optical Coherence
Tomography.
Fig. 3(B): Central macular thickness after
3rd intravitreal injection of AVASTIN was 218 µm showing
significant improvement.
degenerative effects of
intravitreal Ranibizumab in 10 different eyes in patients suffering from
macular edema21. On the other hand, our
study showed improvement in OCT findings and VA in comparatively more patients
(Fig. 3).
CONCLUSION
Anti VEGF injection of bevacizumab
(Avastin) proved to be capable for the management of diabetic macular edema and
improving vision. At the doses of 1.25 mg/0.05 mL, it provided significant
increase in VA and helps in decreasing CMT in DME. We may assume without any
harm that the rate of visual complications were managed with no significant
side effects.
ACKNOWLEDGEMENT
This study was conducted at
Sindh Institute of Ophthalmology and Visual Sciences, Hyderabad, under
directorship of Professor Dr. Khalid Iqbal Talpur.
Financial
Support and sponsorship
Nil.
Conflict
of Interest
There are no conflicts of interest
Author’s
Affiliation
Dr. Rafeen Talpur
FCPS, Ophthalmology, Assistant
Professor
Department
of Ophthalmology, Sindh Institute of Ophthalmology and Visual Sciences Hyderabad.
Dr. Muhammad Jawed
Ph.D Biochemistry and Molecular
Biology Research Associate
Scientific Ophthalmic research
and pathology laboratory,
Sindh Institute of
Ophthalmology and Visual Sciences Hyderabad
Dr. Fariha S. Wali
FCPS, Ophthalmology, Assistant
Professor
Department
of Ophthalmology, Sindh Institute of Ophthalmology and Visual Sciences Hyderabad.
Dr. Faisal Taqvi
FCPS, FRCS, Ophthalmology,
Assistant Professor
Department
of Ophthalmology, Sindh Institute of Ophthalmology and Visual Sciences Hyderabad.
Dr. Shehnilla Shujaat
MS, Ophthalmology, Senior
Registrar
Department
of Ophthalmology, Sindh Institute of Ophthalmology and Visual Sciences Hyderabad.
Role of
Authors
Dr. Rafeen Talpur
Primary investigator
Dr. Muhammad Jawed
Data Analysis, formatting and correspondence
Dr. Fariha S. Wali
Co-investigator
Dr. Faisal Taqvi
Co-investigator
Dr. Shehnilla Shujaat
Co-investigator
REFERENCES
17. Martin
DF. Evolution of Intravitreal Therapy for Retinal Diseases - From CMV to
CNV: The LXXIV Edward Jackson Memorial Lecture. American Journal of
Ophthalmology 2018; 191: xli-lviii.